MARKET

APRE

APRE

Aprea Therapeutics, Inc.
NASDAQ
0.6710
-0.0120
-1.76%
After Hours: 0.6601 -0.0109 -1.62% 19:27 08/13 EDT
OPEN
0.6710
PREV CLOSE
0.6830
HIGH
0.6816
LOW
0.6563
VOLUME
21.28K
TURNOVER
--
52 WEEK HIGH
1.793
52 WEEK LOW
0.5480
MARKET CAP
8.45M
P/E (TTM)
-0.4353
1D
5D
1M
3M
1Y
5Y
1D
Aprea Therapeutics Price Target Cut to $3.00/Share From $6.00 by Wedbush
Dow Jones · 12h ago
Aprea Therapeutics Is Maintained at Outperform by Wedbush
Dow Jones · 12h ago
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3
Benzinga · 13h ago
Analysts Offer Insights on Healthcare Companies: Kailera Therapeutics, Inc. (KLRA), Warby Parker (WRBY) and Aprea Therapeutics (APRE)
TipRanks · 14h ago
Aprea Advances APR-1051; Phase 1 Enrollment Accelerates
NASDAQ · 1d ago
Aprea Therapeutics advances APR-1051 oncology pipeline progress
TipRanks · 1d ago
Aprea Therapeutics GAAP EPS of -$0.07 beats by $0.16
Seeking Alpha · 1d ago
Press Release: Aprea Therapeutics Announces Second Quarter 2026 Financial Results
Dow Jones · 1d ago
More
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.

Webull offers Aprea Therapeutics Inc stock information, including NASDAQ: APRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APRE stock methods without spending real money on the virtual paper trading platform.